about
New era for management of chronic hepatitis C virus using direct antiviral agents: A reviewNational treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians.Endoscopic Ultrasound-Guided Fine Needle Aspiration versus Percutaneous Ultrasound-Guided Fine Needle Aspiration in Diagnosis of Focal Pancreatic Masses.Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt.Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in EgyptThe future for the treatment of genotype 4 chronic hepatitis C.How to optimize HCV therapy in genotype 4 patients.Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues.After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal.Safety of direct antiviral agents in the management of hepatitis C.Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection.Microwave ablation in the spleen versus partial splenic artery embolisation: A new technique for hypersplenism in cirrhosis.Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.Herpes Zoster reactivation in patients with chronic hepatitis C under treatment with directly acting antiviral agents: A case series.Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.A new potent NS5A inhibitor in the management of hepatitis C virus: ravidasvir.Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis.Egyptian liver library: Rebuilding the pyramid of liver disease evidence in Egypt.Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data.MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection.Towards hepatitis C virus elimination: Egyptian experience, achievements and limitationsFive Fibrosis Biomarkers Together with Serum Ferritin Level to Diagnose Liver Fibrosis and CirrhosisManaging diabetes and liver disease associationImpact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-reviewAn account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens.HCV in Egypt, prevention, treatment and key barriers to eliminationLetter: concordance of SVR4 and SVR12 following direct-acting anti-viral treatment in EgyptSafety-Engineered Syringes: An Intervention to Decrease Hepatitis C Burden in Developing Countries-A Cost-Effectiveness Analysis From EgyptCorrection to: Prevalence of prolonged QT interval in patients with HCV-related chronic liver diseaseReal-Life Efficacy of 5 Different Antiviral Regimens for Treatment of Chronic Hepatitis C With Normal Liver EnzymesAlcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies WorldwideSerum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients with Chronic Hepatitis C: Real-world Results from 1716 Patients in EgyptHepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With WolvesEmergency endoscopic variceal band ligation in a COVID-19 patient presented with hematemesis while on mechanical ventilationManaging diabetes and liver disease association: Practice guidelines from the Egyptian Association for the Study of Liver and Gastrointestinal Disease (EASLGD)
P50
Q26800050-99F7E074-2B86-4F34-A047-697C6E5499AEQ30238676-EBD5B580-4EE4-4559-9A63-5B0C7C8B4F15Q33389244-C1287CBB-7F15-4B18-A74D-F5157BA9B043Q33772939-63457B77-4D54-484F-A2B9-16CDC9904198Q35122424-AC8A497E-3EE6-4A82-AE8A-B8DA7784C112Q36256411-25D3AEA4-7C4A-44F8-ACCA-B05503844235Q37972775-9F124AAE-681C-4A75-8B27-E0B3BAC782FFQ38071388-E581B2D1-723A-4AD4-9B67-673B46A4CF6AQ38174246-70A9CCD2-DB69-4650-999A-1CB9BED68468Q38655638-F251D2B8-C9B0-47E2-AE73-F94D1C8F2F88Q38818416-D5D06628-DF7F-4068-AD4B-DB89DD8222ADQ38821075-BC718F2A-BF8B-4F4C-958C-E54D779CA396Q38882309-60CEDF8D-A150-4577-BA81-9DEF26720DACQ38948533-6DE8CA40-BED6-4248-92C1-C6D36DF9AAEAQ38984867-260369F0-A69B-424B-98E6-870F0ECE9F20Q38991020-126829CF-2522-415A-B6D5-AED5013F8040Q38995251-7072D60A-B113-4026-A8DD-C106B67A0F2BQ40123051-ED0D333C-29F0-47A5-A4BA-389BEFC0461CQ42203834-6CFB561F-E248-4219-BDCD-BB8604040BADQ46445455-8C667E12-B6D4-4588-8D7B-EF564940432FQ47550461-AF24B35B-4D6E-4AA2-A9FD-05B2266DC782Q47560916-28D681B7-4E30-4840-9189-9689FB07D230Q49665323-B335D25F-5B5B-4048-915E-85D4390C7DDEQ54218120-273C8BBE-5C68-4711-B270-C6CBFF98FD99Q54256847-AE765B44-257D-426E-A522-ACBB88BD2061Q57815114-77477C23-83A7-40D3-93BC-92B6A127A581Q58590630-8638655F-EF12-4E02-8808-CE3E580FA15FQ59351226-697A08D6-110A-4F19-843E-BEB07D921EDAQ64266136-BDAA047E-A892-4106-A017-51E832D0C96AQ64985697-F6778F07-C7CD-409E-B0F2-D6CCFEF9094EQ87967968-71E82133-0E6D-4145-93E3-2CA460EEC84EQ89023024-9596D2C2-83E4-41FC-96F5-3AB27FFA6270Q90016593-914A58CE-473F-4802-B568-5231C360C57CQ91002798-9149A08E-83CE-48F0-BD33-EF14BA04F794Q91035654-167BBA8D-F31C-4C5A-AD6B-82B32CCE1FD7Q91305969-3AEAA795-4D2D-40FC-B8A9-7788FBC1A06AQ91384804-290EACA8-EEA8-4050-9B7A-BE01DEDC949AQ91832147-26411B93-0721-44C2-A508-54B9B5ABCC91Q91918961-33B1FBBC-AD84-4A72-A888-4026AAD67323Q92244930-864324B0-7D3F-4C3E-A595-29B01833FD46
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mohamed El Kassas
@ast
Mohamed El Kassas
@en
Mohamed El Kassas
@es
Mohamed El Kassas
@nl
Mohamed El Kassas
@sl
type
label
Mohamed El Kassas
@ast
Mohamed El Kassas
@en
Mohamed El Kassas
@es
Mohamed El Kassas
@nl
Mohamed El Kassas
@sl
prefLabel
Mohamed El Kassas
@ast
Mohamed El Kassas
@en
Mohamed El Kassas
@es
Mohamed El Kassas
@nl
Mohamed El Kassas
@sl
P106
P1153
26323643100
P31
P496
0000-0002-3396-6894